KR20190140907A - 그랜자임 b 억제제 조성물 및 피부의 수포발생 및/또는 피부의 박리를 예방 및/또는 치료하는 방법 - Google Patents

그랜자임 b 억제제 조성물 및 피부의 수포발생 및/또는 피부의 박리를 예방 및/또는 치료하는 방법 Download PDF

Info

Publication number
KR20190140907A
KR20190140907A KR1020197028544A KR20197028544A KR20190140907A KR 20190140907 A KR20190140907 A KR 20190140907A KR 1020197028544 A KR1020197028544 A KR 1020197028544A KR 20197028544 A KR20197028544 A KR 20197028544A KR 20190140907 A KR20190140907 A KR 20190140907A
Authority
KR
South Korea
Prior art keywords
administration
gzmb
skin
composition
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197028544A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 제임스 그랜빌
발레리오 루소
웨 선
Original Assignee
더 유니버시티 오브 브리티시 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 브리티시 콜롬비아 filed Critical 더 유니버시티 오브 브리티시 콜롬비아
Publication of KR20190140907A publication Critical patent/KR20190140907A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197028544A 2017-02-28 2018-02-28 그랜자임 b 억제제 조성물 및 피부의 수포발생 및/또는 피부의 박리를 예방 및/또는 치료하는 방법 Withdrawn KR20190140907A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465055P 2017-02-28 2017-02-28
US62/465,055 2017-02-28
US201762611188P 2017-12-28 2017-12-28
US62/611,188 2017-12-28
PCT/CA2018/050230 WO2018157244A1 (en) 2017-02-28 2018-02-28 Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling

Publications (1)

Publication Number Publication Date
KR20190140907A true KR20190140907A (ko) 2019-12-20

Family

ID=63369653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028544A Withdrawn KR20190140907A (ko) 2017-02-28 2018-02-28 그랜자임 b 억제제 조성물 및 피부의 수포발생 및/또는 피부의 박리를 예방 및/또는 치료하는 방법

Country Status (8)

Country Link
US (2) US20200016125A1 (enExample)
EP (1) EP3589304A4 (enExample)
JP (2) JP2020510655A (enExample)
KR (1) KR20190140907A (enExample)
AU (1) AU2018229079A1 (enExample)
IL (1) IL268860A (enExample)
MX (1) MX2019010230A (enExample)
WO (1) WO2018157244A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021050978A1 (en) * 2019-09-11 2021-03-18 University Of Cincinnati Treatment of skin blistering diseases using antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015296675B2 (en) * 2014-08-01 2020-04-30 Vida Therapeutics, Inc. Cyclic urea compounds as Granzyme B inhibitors
US20190038602A1 (en) * 2016-02-03 2019-02-07 Vida Therapeutics, Inc. Granzyme b inhibitor formulations and methods for the treatment of burns

Also Published As

Publication number Publication date
EP3589304A4 (en) 2020-11-25
AU2018229079A1 (en) 2019-10-10
US20200016125A1 (en) 2020-01-16
JP2020510655A (ja) 2020-04-09
WO2018157244A1 (en) 2018-09-07
MX2019010230A (es) 2019-11-21
JP2023062141A (ja) 2023-05-02
EP3589304A1 (en) 2020-01-08
IL268860A (en) 2019-10-31
US20230233526A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US7879863B2 (en) Aniline derivatives
JP7362611B2 (ja) 非アルコール性脂肪肝疾患及び線維症の治療及び予防のためのペプチド
CN104755464B (zh) 聚蛋白多糖酶抑制剂
JP7691928B2 (ja) キナーゼ阻害剤
JP2017512757A (ja) 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
JP2016534069A (ja) Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
KR20240007251A (ko) G-단백질 결합 수용체의 조절제
ES2285841T3 (es) Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
KR20170084067A (ko) C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
JP2006525362A (ja) 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
US20230233526A1 (en) Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling
Park et al. Benzbromarone induces targeted degradation of HSP47 protein and improves hypertrophic scar formation
AU2012219582A1 (en) Methods for treating and diagnosing disease
AU2019310919B2 (en) Compounds for use in treating kidney disorders
US20240245682A1 (en) Alpha-v-beta-8 integrin inhibitors and uses thereof
EP3156064B1 (en) Application of yb-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease
Nyström et al. Skin blistering and collagens: from bench to therapies
CN103370331B (zh) 用于治疗关节病的氨基他汀衍生物
JP2023538612A (ja) 糖尿病治療及びベータ細胞再生のための方法及び組成物
KR100574597B1 (ko) α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
CN119451944A (zh) Prep结合配体
CN118852326A (zh) 一种靶向降解PI3K 110β的PROTAC化合物及其制备方法和应用
WO2014000027A1 (en) Prevention and treatment of haematological conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202